[Applications of molecular biology to care of patients with malignant hematological disease].
The improvement of the techniques of molecular biology allowed greater performances in the field of detection and characterization of chromosomal abnormalities and/or molecular defects observed in human hematological malignancies. Cytological and immunophenotypical results are reinforced by data obtained with standard and molecular cytogenetic tools and with PCR based techniques. Molecular data are usefull at diagnosis in order to define different types of leukemias and to score patient prognosis. Therefore, these techniques help to choose among various therapeutic options. In post induction treatment period, PCR tools allowed to measure minimal residual disease (MRD) and to distinguish new prognosis factors essential for patient's management.
Féger
F
F
Laboratoire d'hématologie cellulaire et moléculaire, CNRS FRE 2444 Hématopoïèse, cytokines et inflammation, Faculté des Sciences pharmaceutiques et biologiques, 4, avenue de l'Observatoire, F 75270 Paris Cedex 06, France.
D000818:Animals; D015415:Biomarkers; D019337:Hematologic Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008967:Molecular Biology
D015415:Biomarkers